Abstract:BACKGROUND:During the transfusion of blood components, the transfer of allogeneic donor white blood cells (WBCs) can mediate transfusion-associated graft-versus-host disease (TA-GVHD). To minimize the reaction, exposure of blood products to gamma irradiation is currently the standard of care. The aim of our study was to evaluate and compare hemostatic function, transfusion efficacy, and safety of gamma-irradiated single-donor apheresis platelet concentrates (PCs) and of conventional non-irradiated PCs in patients with chemotherapy-induced thrombocytopenia. METHODS:20 double-dose single-donor leukoreduced PCs were split in two identical units; one was gamma-irradiated with 25 Gy (study arm A) and the other remains non-irradiated (study arm B). Both units were stored under equal conditions. Hematologic patients were randomly assigned to receive gamma-irradiated or conventional non-irradiated PCs. Hemostatic function was evaluated by thrombelastography (TEG). TEG measurements were taken pre transfusion and 1 and 24 h post transfusion. TEG profiles were measured, noting the time to initiate clotting (R), the angle of clot formation (α), and the maximum amplitude (clot strength (MA)). Whole blood samples were collected from these thrombocytopenic patients at 1 and 24 h for PLT count increments (CIs) and corrected count increments (CCIs) with assessments of transfusion efficacy. Time to next PLT transfusion, transfusion requirement of RBCs, active bleeding, and adverse events (AEs), were analyzed. RESULTS:No differences could be found in hemostatic function parameters (MA, R, and α) between study arms A and B (all p values > 0.096) pre transfusion as well as 1 and 24 h post transfusion. No differences between study arms A and B were observed for mean (± standard deviation (SD)) 1-hour CCI (12.83 ± 6.33 vs. 11.59 ± 5.97) and 24-hour CCI (6.56 ± 4.10 vs. 5.76 ± 4.05). Mean 1-hour CI and 24-hour CI were not significantly different in both study arms (p = 0.254 and p = 0.242 respectively). Median time to the next PC transfusion after study PC was not significantly different between groups: (2.4 vs. 2.2 days, p = 0.767). No differences could be found in transfusion requirement of red blood cells (p = 0.744) between both study arms. There were also no regarding bleeding, adverse events, and acute transfusion reaction(s). CONCLUSIONS:This study confirms safety of gamma-irradiated PCs for treatment thrombocytopenia. Hemostatic function, transfusion efficacy, bleeding, and safety of single-donor apheresis PCs treated with gamma irradiation versus untreated control PCs are comparable.

Isohemagglutinin titration in pooled and apheresis platelets

Platelet Additive Solutions as an Alternative Storage Medium of Apheresis Platelets to Reduce ABO Antibody Titer for ABO-Incompatibility Platelet Transfusion

The safety of ABO minor incompatible platelets transfusions using a rapid infuser

Platelet transfusions in haploidentical haematopoietic stem cell allograft candidates: Protecting HLA‐A and HLA‐B antigens through eplet analysis

Improving platelet function following prophylactic platelet transfusion in patients with hematological malignancies

Utility of acid citrate dextrose‐acidification for platelet volume reduction protocols in the transfusion service

Absolute Immature Platelet Counts in the Setting of Suspected Heparin-Induced Thrombocytopenia May Predict Anti-Pf4-heparin Immunoassay Testing Results

Preparation and storage characteristics of white cell-reduced high-concentration platelet concentrates collected by anapheresis system for transfusions in utero

Platelet sequestration with a new-generation autotransfusion device

Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use

The impact of pathogen‐reduced platelets in acute leukaemia treatment on the total blood product requirement: a subgroup analysis of an EFFIPAP randomised trial

Comparison of manual titrations to automated microplate and gel titration assays used in the screening of blood donors for production of Low‐Titer O Whole Blood

Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor

Hemostatic function and transfusion efficacy of apheresis platelet concentrates treated with gamma irradiation in use for thrombocytopenic patients.

Qualities and Curative Effects of Single Donor Platelets and Buffy-coat-collected Platelets Concentrates

Impact of Plateletpheresis on the Hemoglobin, Hematocrit, and Total Red Blood Cell Count: An Updated Meta-Analysis

Assessment of the soluble proteins HMGB1, CD40L and CD62P during various platelet preparation processes and the storage of platelet concentrates: The BEST collaborative study

Platelets retain function and can be stored following disruption of human leucocyte antigens

Alloimmunization Induced by RhD Antigens During Apheresis Platelet Concentrates Transfusion and Its Clinical Application

Concentrations of Blood Components in Commercial Platelet-Rich Plasma Separation Systems: A Review of the Literature

Acute Pulmonary Injury in Hematology Patients Supported with Pathogen Reduced and Conventional Platelet Components